Table 1. Participant characteristics: total study population versus microarray sample.
| Total study population at screening (n=800) | Microarray sample (n=174) | |
|---|---|---|
| Demographics | ||
| Median age (range); years | 25 (18–45) | 27 (18–47) |
| Marital status: married or steady partner | 278 (34.9) | 68 (39.1) |
| Divorced/separated/widowed | 210 (26.3) | 40 (23) |
| Never married | 584 (73.0) | 131 (75.3) |
| Median income per week (IQR); × 1000 RWFa | 15 (8–23) | 12 (8–20) |
| Education levela: no education | 166 (20.9) | 43 (24.7) |
| Some primary school but not completed | 326 (41.1) | 71 (40.8) |
| Completed primary and/or started secondary | 301 (38.0) | 60 (34.5) |
| Currently pregnant | 61 (7.6) | 22 (12.6) |
| Median number of lifetime pregnancies (IQR)a | 2 (1–3) | 2 (1–3) |
| Recent change in reproductive intentionsb | 7 (1.8) | 7 (4.0) |
| Sexual risk taking | ||
| Median years in sex worka,c (IQR) | 3 (2–5) | 3 (2–5) |
| Currently working as sex worker | 787 (99.4) | 148 (85.1) |
| Washed inside vagina in last 3 monthsb | 355 (92.9) | 160 (92) |
| Median frequency of washing inside vagina in week prior to enrollment (IQR)a | 7 (7–12) | 7 (7–7) |
| Median number of sex acts in past month (IQR) | 40 (20–64) | 20 (12–40) |
| Condom use at last sex acta | 593 (74.1) | 127 (73.0) |
| Consistent condom useb,d | 173 (46.5) | 60 (37.3) |
| Clinical characteristics | ||
| Genitourinary symptoms in month prior to enrollmenta | 155 (19.8) | 39 (23.1) |
| Genitourinary symptoms in last 3 monthsb | 50 (13.0) | 33 (19.0) |
| Pelvic examb: abnormal vaginal discharge | 44 (11.7) | 23 (13.2) |
| Abundant cervical mucus | 15 (4.0) | 7 (4.0) |
| Vaginal pH >4.5 | 303 (81.7) | 137 (79.2) |
| Antibiotics use during past 14 days | 1 (0.1) | 1 (0.6) |
| Laboratory diagnoses | ||
| Any viral STI | 510 (65.6) | 154 (88.5) |
| HIV | 192 (24.0) | 64 (36.8) |
| HSV-2 | 485 (60.6) | 137 (78.7) |
| HPV | 183 (48.8) | 83 (47.7) |
| Any bacterial STI (HIV-negative women only)b,e | 105 (28.9) | 38 (51.4) |
| Treponema pallidum | 25 (6.6) | 6 (8.7) |
| Neisseria gonorrhoeae | 29 (7.9) | 12 (16.7) |
| Chlamydia trachomatis | 17 (4.6) | 9 (12.3) |
| Trichomonas vaginalis | 61 (16.2) | 22 (26.5) |
| Abnormal cervical cytologyb,f | 10 (2.8) | 10 (6.2) |
| Wet mountb | ||
| Yeasts | 17 (4.5) | 11 (6.3) |
| Positive whiff test | 25 (6.6) | 8 (4.6) |
| Clue cells >20% | 65 (17.2) | 26 (14.9) |
| Bacterial vaginosis by Nugent scoringb,g | ||
| Negative (0–3) | 159 (44.8) | 73 (42.4) |
| Intermediate (4–6) | 53 (14.9) | 19 (11) |
| Positive (7–10) | 143 (40.3) | 80 (46.5) |
Abbreviations: HPV, human papillomavirus; HSV, herpes simplex virus; IQR, interquartile range; RWF, Rwandan francs; STI, sexually transmitted infection.
Cells represent number and percentage unless stated otherwise.
a
Baseline values are reported.
b
Only assessed during follow-up; values reported for the HIV-negative cohort at M6 (n=387).
c
47/800 values of total population and 11/174 of microarray-tested women missing.
d
Sexually active women only.
e
Only tested in HIV-negative cohort at M6 (n=363, of which 83 microarray-tested).
f
12/174 values of microarray-tested women missing.
g
32/387 values missing.